Covestor LTD Collegium Pharmaceutical, Inc Transaction History

Covestor LTD

$160 Million
Q4 2024

A detailed history of Covestor LTD transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Covestor LTD holds 395 shares of COLL stock, worth $11,751. This represents 0.01% of its overall portfolio holdings.

Number of Shares

395

Previous 373 5.9%

Holding current value

$11,751

Previous $14,000 21.43%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$28.61 - $41.86 $629 - $920	22 Added 5.9%	395 $11,000
Q3 2024 Nov 01, 2024	BUY	$31.4 - $39.07 $596 - $742	19 Added 5.37%	373 $14,000
Q2 2024 Aug 09, 2024	BUY	$31.36 - $39.99 $407 - $519	13 Added 3.81%	354 $11,000
Q1 2024 May 10, 2024	SELL	$31.23 - $40.91 $1,186 - $1,554	-38 Reduced 10.03%	341 $13,000
Q4 2023 Feb 09, 2024	BUY	$21.16 - $30.8 $1,121 - $1,632	53 Added 16.26%	379 $12,000
Q3 2023 Nov 13, 2023	BUY	$21.23 - $24.28 $403 - $461	19 Added 6.19%	326 $8,000
Q2 2023 Aug 11, 2023	BUY	$21.06 - $24.0 $5,559 - $6,336	264 Added 613.95%	307 $6,000
Q1 2023 May 15, 2023	SELL	$23.0 - $29.88 $2,116 - $2,748	-92 Reduced 68.15%	43 $1,000
Q4 2022 Feb 13, 2023	SELL	$16.14 - $23.55 $1,936 - $2,826	-120 Reduced 47.06%	135 $3,000
Q3 2022 Nov 14, 2022	BUY	$15.46 - $20.1 $3,849 - $5,004	249 Added 4150.0%	255 $4,000
Q2 2022 Aug 10, 2022	SELL	$14.22 - $20.88 $369 - $542	-26 Reduced 81.25%	6 $0
Q1 2022 May 13, 2022	SELL	$17.2 - $22.5 $34 - $45	-2 Reduced 5.88%	32 $1,000
Q4 2021 Feb 10, 2022	BUY	$17.5 - $21.35 $595 - $725	34 New	34 $1,000

Others Institutions Holding COLL

# of Institutions

246

Shares Held

37.2M

Call Options Held

59.3K

Put Options Held

9.5K

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.02B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account